| Ytd | 20.91% | |
| 1y | 173.66% |
| Open | 6.76 | Prev Close | 6.81 | Low | 6.56 | High | 6.85 | Mkt Cap | 1.91B |
| Vol | 3.00M | Avg Vol | 3.03M | EPS | -0.38 | P/E | N/A | Forward P/E | -15.29 |
| Beta | 1.18 | Short Ratio | 15.84 | Inst. Own | 86.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 6.16 | 200-d Avg | 5.02 | 1yr Est | 13.00 |
Taysha Gene Therapies (TSHA) remains a "Buy," driven by strong TSHA-102 data in Rett Syndrome and pi
Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and rai
Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact
U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release a
Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology co
BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform
B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy a
Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outp
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology c
U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls afte